Heron Therapeutics (HRTX) Shares Outstanding (2011 - 2026)

Heron Therapeutics (HRTX) has 16 years of Shares Outstanding (Entity) data on file, last reported at $188.6 million in Q1 2026.

• Quarterly Shares Outstanding (Entity) rose 23.72% year-over-year to $188.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $188.6 million (up 23.72% YoY) and the FY2025 annual result came in at $188.3 million, up 23.79% from the prior year.
• Shares Outstanding (Entity) steadied at $188.6 million in Q1 2026, from $188.3 million in the prior quarter.
• In the past five years, Shares Outstanding (Entity) ranged from a high of $188.6 million in Q1 2026 to a low of $108876.0 in Q4 2022.
• A 5-year average of $136.8 million and a median of $150.4 million in 2024 frame the typical range for Shares Outstanding (Entity).
• Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) tumbled 99.89% — and 2023, when it soared 137933.18%.
• Tracing HRTX's Shares Outstanding (Entity) over 5 years: stood at $108876.0 in 2022, then soared by 137933.18% to $150.3 million in 2023, then climbed by 1.23% to $152.1 million in 2024, then grew by 23.79% to $188.3 million in 2025, then climbed by 0.14% to $188.6 million in 2026.
• The last three Shares Outstanding (Entity) figures came in at $188.6 million (Q1 2026), $188.3 million (Q4 2025), and $183.3 million (Q3 2025), per Business Quant data.